CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Hypercholesterolaemia - familial - How up-to-date is this topic?
Changes
Version 1.2, revision planned in 2013.
Last revised in March 2009
December 2010 — minor update. Following the publication of the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial [SEARCH Collaborative Group, 2010], the Supporting evidence section has been updated. Issued in December 2010.
June 2010 — minor update. Following a review of the data from the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial [Clinical Trial Service Unit, 2008], the Medicines and Healthcare products Regulatory Agency (MHRA) has advised that simvastatin 80 mg should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks [MHRA, 2010]. Issued in June 2010.
October 2009 — minor update. A reminder from the MHRA [MHRA, 2009] that aspirin is not licensed for use in primary prevention of vascular events has been added. Issued in October 2009.
November 2008 to March 2009 — this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.
© NHS Institute for Innovation and Improvement